Welcome to our dedicated page for Alpine Immune Sc news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sc stock.
Alpine Immune Sciences (ALPN) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies targeting cancer, autoimmune diseases, and inflammatory conditions. This page provides investors and researchers with timely updates on ALPN's scientific advancements, strategic partnerships, and clinical milestones.
Access verified press releases and news articles covering key developments, including clinical trial progress, regulatory updates, and collaborative research initiatives. Our curated collection ensures transparent access to essential information for evaluating ALPN's position in the immunotherapy landscape.
Explore updates on ALPN's recombinant protein-based therapies and immune synapse modulation approaches. Content spans preclinical breakthroughs, Phase 1-3 trial results, licensing agreements, and financial disclosures – all critical for understanding the company's trajectory.
Bookmark this page for streamlined tracking of ALPN's progress in developing targeted treatments for complex disorders. Regular updates provide insights into the company's scientific rigor and its potential to address unmet medical challenges through immunological innovation.
Alpine Immune Sciences (NASDAQ:ALPN) presented two significant oncology posters at the AACR Virtual Annual Meeting I, April 10-15, 2021. The first highlights the NEON-1 Phase I trial of ALPN-202, focusing on advanced malignancies, with no dose-limiting toxicities reported. The second showcases engineered fusion proteins that enhance tumor immune responses. President Stanford Peng expressed optimism about advancing clinical data for ALPN-202 in future meetings, reflecting the company's commitment to innovative immunotherapy solutions.
Alpine Immune Sciences (NASDAQ: ALPN) reported a transformative year in 2020, focusing on innovative therapies for cancer and autoimmune diseases. They plan to initiate an international Phase 2 trial for ALPN-101 in systemic lupus erythematosus and continue their Phase 1 study for ALPN-202. The company raised $60 million from a private placement and formed an exclusive license agreement with AbbVie for ALPN-101, potentially worth $805 million. Financially, they reported $131.4 million in cash and a rise in collaboration revenue to $9.3 million, while net losses decreased from $41.9 million in 2019 to $27.9 million in 2020.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will release its fourth quarter and full year 2020 financial results on March 18, 2021, after market close. The company will host a conference call and live webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. Investors can access the call via phone or through a webcast on the company's investor relations page. A replay will be available for 90 days post-event. Alpine aims to lead in immunotherapy with a strong R&D platform and collaborations in the biopharmaceutical sector.
Alpine Immune Sciences (NASDAQ:ALPN) announced its participation in the AACR Virtual Annual Meeting I, scheduled for April 10-15, 2021. The company will present two posters: one on the Phase 1 NEON-1 study of ALPN-202, a dual checkpoint inhibitor for advanced malignancies, and another detailing a preclinical study on engineered fusion proteins for anti-tumor immunity. ALPN-202 aims to enhance checkpoint inhibition effectiveness while minimizing toxicities, with promising preclinical efficacy demonstrated.
Alpine Immune Sciences (NASDAQ:ALPN) has announced its participation in three upcoming virtual healthcare conferences. The events include the Cowen 41st Annual Virtual Health Care Conference on March 1, 2021, featuring a Novel IO Panel at 10:20 a.m. ET; the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, with an on-demand company presentation starting at 7:00 a.m. ET; and the Oppenheimer 31st Annual Virtual Healthcare Conference on March 17, 2021, at 1:50 p.m. ET. Webcasts of the presentations will be available for 90 days online.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has appointed Pamela Holland, Ph.D., as Senior Vice President of Research. Dr. Holland brings extensive experience in cancer biology, crucial for advancing the company’s immunotherapy portfolio, including ALPN-101 and ALPN-202. Additionally, Remy Durand, Ph.D., has been promoted to Chief Business Officer, playing a key role in corporate strategy and partnerships. Both appointments aim to strengthen and accelerate the research and development efforts at Alpine, positioning the company for significant advancements in 2021.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a clinical-stage immunotherapy company, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:00 p.m. ET. The presentation will highlight their innovative treatments for cancer and autoimmune diseases. A live webcast can be accessed in the investor relations section of their website, with a replay available for 90 days post-event. Alpine is recognized for its unique protein engineering technologies aimed at developing first- or best-in-class immunotherapies.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has appointed Natasha A. Hernday to its Board of Directors. With over 20 years of experience in corporate development, including her role at Seagen, Hernday's expertise is expected to enhance Alpine's strategic direction. This leadership change coincides with Paul Sekhri stepping down from his board position after serving since February 2016. Executive Chairman Mitchell H. Gold emphasized the timing of this transition as vital for advancing Alpine's pipeline and building on its partnership with AbbVie.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced its participation in the Evercore ISI 3rd Annual HealthCONx Virtual Conference, scheduled for December 3, 2020, at 4:45 p.m. ET. Members of the senior leadership team will engage in an analyst-led fireside chat. Investors can access a live webcast through the company’s investor relations website, with a replay available for 90 days after the event. Alpine focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases, leveraging unique protein engineering technologies.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place from December 1-3, 2020. The event will include a fireside chat, accessible online during the week of November 23 via the company's investor relations webpage. Alpine is focused on developing immunotherapies for cancer and autoimmune diseases, leveraging innovative protein engineering technologies to enhance patient care.